Drugs / TQB3915
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05416359 | Jun 2022 → Jun 2023 | cancer | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TQB3915 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05416359 ↗ |
| Route | Oral | “Oral administration on an empty stomach” NCT05416359 ↗ |